Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging

NCT06804759 · tracked via the Priya Life Science USA tracker
Sponsor
Victoria Collotta
Phase
Not applicable
Started
2024-11-18
Last updated
2025-02-03

Condition(s) studied

Skin Aging

Investigational drug(s) / intervention(s)

Investigational Facial Serum #1Investigational Facial Serum #2Investigational Facial Serum #3

Investigational Facial Serum #1: Investigational Facial Serum #1 is made with Activated Silk™ 27P-α.

Investigational Facial Serum #2: Investigational Facial Serum #2 is made with an active comparator.

Investigational Facial Serum #3: Investigational Facial Serum #3 is a placebo comparator

Study summary

A clinical study with approximately 40 subjects, aged 35-65 years of age, who must have crow's feet and at least one other type of facial fine lines/wrinkles in order to evaluate the efficacy of Activated Silk™ 27P-α to improve the signs of aging.

Eligibility

Sex
ALL
Min age
35 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy individuals, between the ages of 35 - 65 years of age, with no known medical conditions that interfere with study participation, are the priority. * Subject has signed a written Informed Consent prior to Day -7. * 100% of subjects have crow's feet and at least one of the following: forehead lines/wrinkles (e.g. vertical lines between eyebrows, horizontal lines above the eyebrow), marionette lines, nasolabial folds. * 50% of subjects have self-perceived sensitive skin. * 20% of the subjects are not 100% caucasian. Exclusion Criteria: * Subject is pregnant, nursing, or planning to become pregnant. * Subject is currently using medication likely to affect the response to investigational formulation. * Subject had a fever in the last 12 hours prior to the start of the study. * Subject has a pacemaker or significant medical history of hepatic, renal, cardiac, pulmonary, digestive, hematological, neurological, locomotor or psychiatric disease; cancer; multiple sclerosis; high blood pressure; thrombosis; phlebitis (inflammation of a vein); insulin-dependent diabetes; or any such related medical condition(s) that may interfere with the completion of the study. * The Subject used a form of retinol on their face in the past six months. * The Subject used any prescription skincare products on their face in the last six months. * The Subject has received any laser, chemical peel, or other facial resurfacing treatment such as microdermabrasion, dermablading or microneedling in the past four weeks. * The Subject received Botox, Dysport, other muscle relaxers or injectable skin fillers in the face during the past six months. * Subject has a known allergy or sensitivity to any ingredient in the aqueous skincare formulation provided for their use in the trial . * Subject is currently participating in another study utilizing facial products. * Subject is blind, visually impaired or decisionally impaired.

Primary outcome measure(s)

  • Change in appearance of fine lines/wrinkles as evaluated by the Principal Investigator using a scale from 0-9 — Day 0 to Day 28
    Change in appearance of fine lines/wrinkles for subjects treated with Investigational Facial Serum #1 vs. Investigational Facial Serum #2 at Day 28 vs. Day 0.

Trial sites (1)

FacilityCityRegionStatus
Evolved By Nature Needham Massachusetts
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06804759 on ClinicalTrials.gov ↗ ← All trials in the USA